Weekly @entity1311 ( XXXX ) with or without trastuzumab (Herceptin) in @entity0 : a community-based observation study.

@entity1 @entity137 @entity0 @entity66 @entity4349 @entity1311 @entity1395 @entity3907 @entity2359 @entity1722
BACKGROUND: We evaluated the efficacy and safety of weekly @entity1311 therapy in @entity1 with locally advanced or metastatic @entity0 in an unselected hospital-based @entity1 population. @entity1 AND METHODS: Using a specific search tool we were able to find 49 cases in our department-based database MedicoHelp containing more than 36,000 files. All cases were evaluable. The mean number of involved sites was 2.4 (range 1-4) and 38/49 @entity1 had @entity66 . 44 @entity1 received prior antitumor therapies, 33 @entity1 had received prior @entity4349 - and/or @entity3907 -containing chemotherapy. Weekly @entity1311 was given at a mean dose of 80 mg/m(2) (day 1, 8, 15, repeated every 28 days), 38 @entity1 with @entity1722 overexpression had a combination therapy with trastuzumab (Herceptin). Median treatment duration with @entity1311 was 4.4 months (range 0.25-9 months). A dose reduction was necessary in 5 @entity1 . RESULTS: Therapy was tolerated well, with a 12% incidence of hematologic grade 3/4 @entity137 and 22% cumulative nonhematologic grade 3 @entity137 ( @entity1395 : 5 @entity1 , mucosa/skin: 3 @entity1 , @entity2359 : 3 @entity1 ). Other @entity137 were rare. The overall response rate was 63%. 22% of the @entity1 achieved disease stabilization. Symptom improvement was seen in 73% of @entity1 . The mean time to progression was 6.0 months (range 0.25-23 months). CONCLUSIONS: Weekly @entity1311 (mostly in combination with trastuzumab) is a well-tolerated regimen and had a surprisingly high efficacy in this observation study in heavily pre-treated @entity1 . Symptom improvement was seen in the majority of @entity1 who responded to the treatment.
